Israeli test tells COVID patients their chance of deterioration, on 0-100 scale

A “next-generation” COVID test made in Israel tells coronavirus-infected people how likely they are to deteriorate to serious illness.

The MeMed COVID-19 Severity test received the CE mark on Tuesday, which means it is approved for use in Europe and the UK. It is expected to be greenlighted for Israel in two to three months, and discussions on approval have also started with the US Food and Drug Administration.

Patients give a tenth of a millimeter of blood, a nurse loads it into a cartridge that looks like a TV remote control and places that into a portable machine, and within 15 minutes the results are displayed on a screen.

The machine provides a number between 0 and 100; the higher the number, the higher the chance of deterioration to severe coronavirus. “It doesn’t just describe the severity of the COVID-19 at the moment of the test, but actually predicts what level of illness will unfold over the next two weeks,” Eran Eden, MeMed’s co-founder and CEO, told The Times of Israel.

He said that results are 86 percent accurate.

The technology hinges on research that his company has been conducting for a decade — peer reviewed and published in medical journals including the Lancet — tracking what specific protein levels in the blood indicate about the prospects for certain health conditions. It gathered a mass of data in dozens of medical centers across the world, in a project funded by the US Department of Defense and the European Commission.

The MeMed COVID-19 Severity test machine (courtesy of MeMed)

Doctors and nurses collected blood samples from patients and then documented their health patterns. Eden’s team then built the technology used by the MeMed COVID-19 Severity test, and by an earlier “snuffles” test.

“We already launched a system to determine why a child has snuffles, and tell doctors whether it’s a bacterial infection that needs antibiotics or a viral infection that just needs chicken soup,” Eden said. “This has been deployed in some Israeli medical centers and we’re starting to deploy it in Europe.”

Dr. Eran Eden, MeMed’s co-founder and CEO (right), sitting with the co-founder and CTO Dr. Kfir Oved (courtesy of MeMed)

“Now, we’re leveraging the same technology to go after COVID-19 severity, and there will be many more applications, including other diseases and possibly the next pandemic.

“If you consider that a strong COVID-19 response was needed to ensure hospitals were not overwhelmed, such technology could have helped to use hospital resources more efficiently, by having a better idea of who needed escalation of care,” added Eden.

“What is more, we have seen with the coronavirus that having an early alert — intervening early — helps to bring less severe outcomes. You can better tailor treatment to try to avert serous illness.”

You’re serious. We appreciate that!

That’s why we come to work every day – to provide discerning readers like you with must-read coverage of Israel and the Jewish world.

So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.

For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.

Join Our Community

Join Our Community

Already a member? Sign in to stop seeing this

Source link

What do you think?

Written by Aakash Malu


Leave a Reply

Your email address will not be published. Required fields are marked *





Fintech Firm Behalf Raises $100M To Expand ‘Buy Now, Pay Later’ Option

Paralympic Swimmer To Rep RightHear, An Israeli Accessibility App For The Visually Impaired